Dyne’s Approach to Targeting DM1
Presented on February 5th, 2021.
Speakers include: Josh Brumm, Chief Executive Officer; Romesh Subramanian, PhD, Chief Scientific Officer; Chris Mix, MD, Senior Vice President, Clinical Development; and Molly White, Vice President, Medical Communications & Advocacy. Learn more about Dyne Therapeutics at www.dyne-tx.com.
Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions. Click here to find all our upcoming Meet the DM Drug Developers dates.